### (19) World Intellectual Property **Organization**

International Bureau



# A CORNE CHINECEN IN CORNER THEIR CORNE CORN CORNER IN CORNER CORNER CORNER CORNER CORNER CORNER CORNER CORNER CORNER

(43) International Publication Date 4 November 2004 (04.11.2004)

PCT

### (10) International Publication Number WO 2004/093852 A3

- (51) International Patent Classification7: A61K 31/565, 31/568, A61P 9/00, 35/00, 11/06, 13/12
- (21) International Application Number:

PCT/GB2004/001663

- (22) International Filing Date: 16 April 2004 (16.04.2004)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 0308857.2

16 April 2003 (16.04.2003) GB

- (71) Applicants and
- (72) Inventors: MARGETTS, George [GB/GB]; 44 Broomfield Drive, Billingshurst RH14 9TN (GB). VINSON, Gavin, Paul [GB/GB]; 37 Birchwood Avenue, Muswell Hill, London N10 3BE (GB).

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of

hydrogen or C<sub>1 to 4</sub> alkyl; R<sub>3</sub> is hydrogen, C<sub>1 to 4</sub> alkyl, C<sub>2 to 4</sub> alkenyl or C<sub>2 to 4</sub> alkynyl; R<sub>4</sub> is hydroxyl, C<sub>1 to 4</sub> alkanoyloxy, a group of formula (II) or (III) wherein R<sub>7</sub> is (CH<sub>2</sub>)<sub>n</sub>, where n is an integer of from 0 to 4, R<sub>8</sub> is hydrogen, C 1 to 4 alkyl, hydroxy or NH<sub>2</sub> and R<sub>9</sub> and  $R_{10}$  are the same or different and each is hydrogen or  $C_{1\,to\,4}$  alkyl; or  $R_3$  and  $R_4$  together are oxo, ethylenedioxy or propylenedioxy.



Int элаі Application No PCI/GB2004/001663

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/565 A61K31/568 A61P9/00 A61P35/00 A61P11/06 A61P13/12

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, PAJ, WPI Data, CHEM ABS Data

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to daim No.		
Х	US 2003/050291 A1 (ARAD YADON) 13 March 2003 (2003-03-13)	1-5,7, 12,13,		
Y	page 2, column 2, lines 4-7,21, paragraph 2; claims 5,6	18-21,29 6		
x	GB 2 155 018 A (STERWIN AG) 18 September 1985 (1985-09-18)  page 2, lines 20,21,44-64 page 3, line 3  -/	1,2,7,8, 12-22, 28-31		

Further documents are listed in the continuation of box C.	X Patent family members are listed in annex.				
Special categories of cited documents:					
*A* document defining the general state of the art which is not considered to be of particular relevance  *E* earlier document but published on or after the international filing date  *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  *O* document referring to an oral disclosure, use, exhibition or other means  *P* document published prior to the international filing date but later than the priority date claimed	<ul> <li>*T* later document published after the international filing date or priority date and not in conflict with the application but clied to understand the principle or theory underlying the invention</li> <li>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</li> <li>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</li> <li>*&amp;* document member of the same patent family</li> </ul>				
Date of the actual completion of the international search	Date of mailing of the international search report				
23 July 2004	19/10/2004				
Name and malling address of the ISA  European Patent Office, P.B. 5818 Patentiaan 2  NL – 2280 HV Rijswijk	Authorized officer				
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fex: (+31-70) 340-3016	Allnutt, S				
Arm POT/ICA has a					

Int plonal Application No PC 1/GB2004/001663

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
Y	SUZUKI GEORGE ET AL: "Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure." CIRCULATION, vol. 106, no. 23, 3 December 2002 (2002-12-03), pages 2967-2972, XP002288136 ISSN: 0009-7322 cited in the application page 2967, column 1, lines 6-8	1-11,29		
Υ .	YAMAKADO M ET AL: "Sites of action of beta-melanocyte stimulating hormone in aldosterone biosynthesis in the rat." PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE. SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE (NEW YORK, N. Y.) JUL 1985, vol. 179, no. 3, July 1985 (1985-07), pages 318-323, XP009033422 ISSN: 0037-9727 see abstract, 1. 3-6 page 319, column 2, lines 20-27	1-11,29		
Υ	ROCHA RICARDO ET AL: "Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart." ENDOCRINOLOGY, vol. 143, no. 12, December 2002 (2002-12), pages 4828-4836, XP002288137 ISSN: 0013-7227 cited in the application page 4828, column 1, lines 14-22 page 4833, column 2, lines 1-33	22,25		
Y	ROUSSEAU MICHEL F ET AL: "Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: Results from the RALES neurohormonal substudy."  JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 40, no. 9, 6 November 2002 (2002-11-06), pages 1596-1601, XP002288138 ISSN: 0735-1097 page 1599, column 2, lines 1-7 see abstract page 1600, column 1, lines 1-5,20-31  -/	22,25		

ŀ

Inter | onal Application No PC | / GB2004/001663

C/Continu	glion) BOCHMENTS CONSIDERED TO DE TO	PC1/GB200	47 001003		
C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT  Calegory Citation of document, with Indication, where appropriate of the relevant passages  Relevant to claim No.					
Calegory *	Citation of document, with Indication, where appropriate, of the relevant passages		Relevant to claim No.		
A	LEE A F ET AL: "Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study."  EUROPEAN JOURNAL OF HEART FAILURE: JOURNAL OF THE WORKING GROUP ON HEART FAILURE OF THE EUROPEAN SOCIETY OF CARDIOLOGY. DEC 1999, vol. 1, no. 4, December 1999 (1999-12), pages 401-406, XP002288261 ISSN: 1388-9842 cited in the application abstract		22-24		
A	EP 0 108 606 A (STERWIN AG) 16 May 1984 (1984-05-16) cited in the application page 2, lines 14-20 page 3, lines 1-5 page 5, lines 19-32		13–17		

national application No. PCT/GB2004/001663

Box II Observations where certain claims were found unsearchable (Continuation of Item 2 of first sheet)
This international Search Report has not been established in respect of certain dalms under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: 1,2,3,7,12-21,29 and 30 (partially) because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 29-31 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. X Claims Nos.: 1,2,3,7,12-21,29 and 30 (partially) because they relate to parts of the international Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
that the description of the description in a constant of the description of the content of the c
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest  The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

# FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claims 29-31 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box II.1

Claims Nos.: 1,2,3,7,12-21,29 and 30 (partially)

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Continuation of Box II.2

Claims Nos.: 1,2,3,7,12-21,29 and 30 (partially)

Present claim 1 relates to the treatment of a disease which is not well defined. The use of the definition "angiotensin II releated disease" in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. It is impossible to determine the diseases for which protection might legitimately be sought. The lack of clarity is such as to render a meaningful complete search impossible. Consequently, the search concerning the therapeutic application of the claimed compounds has been restricted to the diseases listed in claims 4-11.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

Inte hal Application No
PCT/GB2004/001663

Patent document Publication		1017 4520017 001005	
Publication date	Patent family member(s)	,	Publication date
A1 13-03-2003	US 200323279	8 A1	18-12-2003
A 18-09-1985	BE 90181 DE 357771 DK 8048 EP 015447 ES 870671 FI 85075	3 A1 0 D1 5 A 6 A2 9 A1 9 A	15-06-1990 26-08-1985 21-06-1990 26-08-1985 11-09-1985 16-09-1987 26-08-1985
	IT 118489 LU 8578 NO 85075	0 B 6 A1 3 A ,B,	26-06-1985 28-10-1987 11-12-1985 26-08-1985 01-03-1985
A 16-05-1984	DE 337831 DK 49968 EP 010860 ES 850448 FI 83402 GB 213058 GR 7968 IE 5620 JP 176176 JP 404307 JP 5909530 NO 83397	8 D1 3 A 6 A1 6 A1 5 A 8 A ,B 8 A1 5 B1 8 C 8 B 0 A	15-11-1988 01-12-1988 03-05-1984 16-05-1984 16-07-1985 03-05-1984 06-06-1984 31-10-1984 22-05-1991 28-05-1993 15-07-1992 01-06-1984 03-05-1984 01-12-1983
	A1 13-03-2003 A 18-09-1985	A1 13-03-2003 US 200323279  A 18-09-1985 AT 5278 BE 90181 DE 357771 DK 8048 EP 015447 ES 870671 FI 85075 GR 85048 IT 118489 LU 8578 NO 85075 PT 8000  A 16-05-1984 AT 3823 DE 337831 DK 49968 EP 010860 ES 850448 FI 83402 GB 213058 GR 7968 IE 5620 JP 176176 JP 404307 JP 5909530 NO 833976	A1 13-03-2003 US 2003232798 A1  A 18-09-1985 AT 52788 T BE 901813 A1 DE 3577710 D1 DK 80485 A EP 0154476 A2 ES 8706719 A1 FI 850759 A GR 850486 A1 IT 1184890 B LU 85786 A1 NO 850753 A ,B, PT 80008 A ,B  A 16-05-1984 AT 38236 T DE 3378318 D1 DK 499683 A EP 0108606 A1 ES 8504486 A1 FI 834025 A GB 2130588 A ,B GR 79688 A1 IE 56205 B1 JP 1761768 C JP 4043078 B JP 59095300 A NO 833976 A